Response to correspondence concerning: 'Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients'

Autor:	D. W. M. Verhagen, Paul H. P. Groeneveld, N. Bokhizzou, C. Koster, G. Hermanides, R. E.P. Theunissen, R. M. Brohet, R. el Moussaoui, Anton S M Dofferhoff, H. Visser, R. Rood, Hannelore I. Bax, A. J.J. Lammers, Robert Jan Hassing, J. Ellerbroek, Kees Brinkman, D.F. Postma, M. van den Berge
Přispěvatelé:	Internal Medicine
Jazyk:	angličtina
Rok vydání:	2021
Předmět:	Microbiology (medical) 2019-20 coronavirus outbreak medicine.medical_specialty Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) MEDLINE COVID-19/drug therapy lcsh:Infectious and parasitic diseases SDG 3 - Good Health and Well-being Chloroquine Internal medicine medicine Humans lcsh:RC109-216 Letter to the Editor SARS-CoV-2 business.industry Hydroxychloroquine General Medicine Icu admission Intensive Care Units Infectious Diseases Hydroxychloroquine/therapeutic use Chloroquine/therapeutic use business medicine.drug
Zdroj:	International Journal of Infectious Diseases International Journal of Infectious Diseases, 103, 478-479. ELSEVIER SCI LTD International Journal of Infectious Diseases, Vol 103, Iss, Pp 478-479 (2021) International Journal of Infectious Diseases, 103, 478-479. Elsevier
ISSN:	1201-9712
DOI:	10.1016/j.ijid.2020.12.008
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76bfbef14dfa2e777c2c306cad5035a4 Zobrazit plný text záznamu